Merck's HCV Strategy Might Be: Get To Market, Then Improve Incrementally
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for intravenous drug users with hepatitis C might be an important niche indication while Merck gets triple combination NDA ready.
You may also be interested in...
No More Nucs: Merck & Co. Cedes HCV Market To Gilead, AbbVie
Pharma ends HCV development, pulling plug on next-generation two-drug and three-drug combos for hepatitis C and rendering the $3.9bn buyout of Idenix in 2014 a failed gambit.
Merck Suit Against Medicare: Constitutional Arguments Are Scathing, But Are They Persuasive?
A suit designed to test the limits of the protections against judicial review that are embedded in the IRA could have more traction, some legal scholars suggest.